Sageworth Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sageworth Trust’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2	Closed	–	–	488
2022 Q4	$0	Buy	+2	New	+$427	﹤0.01%	455

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Sageworth Trust's ALNY Position: Q1 2023 in Review

Sageworth Trust sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2023, closing a stake of 2 shares.

Sageworth Trust first reported a position in ALNY in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 477 funds tracked by Wall St. Rank hold ALNY as of Q1 2023.

Sageworth Trust reported no remaining Alnylam Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Sageworth Trust sold 2 Alnylam Pharmaceuticals shares in Q1 2023.
Sageworth Trust first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Sageworth Trust's Alnylam Pharmaceuticals position peaked at $0 in Q4 2022.
477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2023.

Based on Sageworth Trust's 13F filing for Q1 2023, filed 8 May 2023.